Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study-Reference-Cited by-同舟云学术

Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study

Published:2022-03 Issue: Volume:Volume 9 Page:127-140
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Lin Kongying^ORCID,Wei Fuqun,Huang Qizhen^ORCID,Lai Zisen,Zhang Jinyu,Chen Qingjing,Jiang Yabin,Kong Jie,Tang Shichuan,Lin Jianhuai,Chen Yufeng,Chen Jinhong,Zeng Yongyi

Publisher

Informa UK Limited

Subject

General Medicine

Reference39 articles.

1. Systemic therapy of liver cancer

2. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria

3. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT

4. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need

5. Hepatocellular carcinoma: clinical frontiers and perspectives

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma;Clinics and Research in Hepatology and Gastroenterology;2024-06

2. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus;JAMA Surgery;2024-06-01

3. Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients;The Kaohsiung Journal of Medical Sciences;2024-05-02

4. Surgical management for hepatocellular carcinoma with concurrent portal vein tumour thrombus and bile duct tumour thrombus: a case report;Annals of Medicine & Surgery;2024-04-24

5. Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis;European Journal of Surgical Oncology;2023-12